1. Proteomic Characterization of a Lunasin-Enriched Soybean Extract Potentially Useful in the Treatment of Helicobacter pylori Infection.
- Author
-
Franca-Oliveira G, Monreal Peinado S, Alves de Souza SM, Kalume DE, Ferraz de Souza TL, Hernández-Ledesma B, and Martinez-Rodriguez AJ
- Subjects
- Humans, Antioxidants pharmacology, Anti-Inflammatory Agents pharmacology, Tandem Mass Spectrometry, Reactive Oxygen Species metabolism, Cell Line, Tumor, Seed Storage Proteins pharmacology, Helicobacter pylori drug effects, Helicobacter Infections drug therapy, Glycine max chemistry, Proteomics methods, Plant Extracts pharmacology, Plant Extracts chemistry, Soybean Proteins pharmacology, Anti-Bacterial Agents pharmacology
- Abstract
Helicobacter pylori infection affects over 50% of the world's population and leads to chronic inflammation and gastric disorders, being the main pathogen correlated to gastric cancer development. Increasing antibiotic resistance levels are a major global concern and alternative treatments are needed. Soybean peptides and other compounds might be an alternative in the treatment to avoid, eradicate and/or control symptoms of H. pylori infection. This study aimed to characterize a lunasin-enriched soybean extract (LSE) using proteomics tools and to evaluate its antioxidant, anti-inflammatory and antibacterial properties against H. pylori infection. By LC-MS/MS analysis, 124 proteins were identified, with 2S albumin (lunasin and large-chain subunits) being the fourth most abundant protein (8.9%). Lunasin consists of 44 amino acid residues and an intramolecular disulfide bond. LSE at a low dose (0.0625 mg/mL) reduced ROS production in both H. pylori -infected and non-infected AGS gastric cells. This led to a significant reduction of 6.71% in the levels of pro-inflammatory interleukin (IL)-8. LSE also showed antibacterial activity against H. pylori , which can be attributed to other soybean proteins and phenolic compounds. Our findings suggest that LSE might be a promising alternative in the management of H. pylori infection and its associated symptoms., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF